Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Wy 41770

Known as: Wy-41,770, Wy-41770 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Wy-41,770 [(5H-dibenzo[a,d]cyclohepten-5-ylidene)acetic acid], a novel acrylic acid, was compared to indomethacin and aspirin in… Expand
  • figure I
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2005
2005
Utilizing an adjuvant arthritis model in rats, we examined humoral immunity to collagen and inflammation in animals with active… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1988
1988
The intestinal ulcerogenic activity of the weak prostaglandin synthesis inhibitor drug Wy-41,770 [5H-dibenzo(a,d)-cyclohepten-5… Expand
  • table 1
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
1986
1986
The immunomodulatory effects of Wy-41,770 (5H-dibenzo[a,d]cyclohepten-5-ylidene) acetic acid, were compared to levamisole and… Expand
Is this relevant?
1986
1986
The disposition of (5H-dibenzo[a,d]cyclohepten-5-ylidene)acetic acid (Wy-41,770), an anti-inflammatory agent, was investigated in… Expand
Is this relevant?